To assess the efficacy of temocillin compared to carbapenems for the management of ESBL-E UTI.
Adults with a definite diagnosis of ESBL-E UTI between January-2015 and October-2019 were enrolled in a multicenter retrospective case-control study. Cases were treated with temocillin ≥50% of the effective antibiotic therapy duration. Control exclusively received carbapenem over the effective antibiotic therapy duration.
Study Type
OBSERVATIONAL
Enrollment
144
No intervention
Rate of clinical cure
Number of patient in clinical cure is defined as the resolution of fever and symptoms of UTI present at antibiotic initiation (and no new symptoms) and the absence of clinical or microbiological failure.
Time frame: Day 14 (End of antibiotic treatment according to national recommendations)
Kinetic of fever defervescence
Median fever calculation
Time frame: Baseline (day 0), day 3, day 7, day 14
Inflammatory biomarkers
White blood cells (WBC) count (/mm3)
Time frame: Baseline (day 0), day 3, day 7, day 14
Inflammatory biomarkers
CRP level (mg/l)
Time frame: Baseline (day 0), day 3, day 7, day 14
Length of hospital stay
Mean duration of hospital stay
Time frame: 3 months after UTI diagnosis
Relapse of UTI
Number of patient with a new UTI diagnosis after the end of antibiotic treatment
Time frame: 3 months after antibiotic therapy initiation
Loss to follow-up, re-hospitalization, and mortality (safety endpoints)
Number of loss to follow-up, re-hospitalization, and mortality
Time frame: 3 months after antibiotic therapy initiation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.